broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K71847383-001-12-5
|
ACH-000996
|
HEC251_ENDOMETRIUM
|
HTS002
| 1 | 1.66413 | -0.179775 | -0.059451 | 1.142037 | 0.000038 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000996
|
BRD-K71847383-001-12-5
|
ACH-000622
|
KNS42_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.388223 | -0.147598 | 0.015874 | 1.182435 | 0.033369 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000622
|
BRD-K71847383-001-12-5
|
ACH-000403
|
NCIH747_LARGE_INTESTINE
|
HTS002
| 1 | 1.341018 | 0.245988 | -0.203967 | 1.230065 | 0.002902 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000403
|
BRD-K71847383-001-12-5
|
ACH-000141
|
SNU308_BILIARY_TRACT
|
HTS002
| 1 | 2.19792 | -0.246082 | 0.110336 | 1.314495 | 0.000752 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000141
|
BRD-K71847383-001-12-5
|
ACH-000988
|
MFE319_ENDOMETRIUM
|
HTS002
| 1 | 1.417748 | -0.75312 | 0.141324 | 1.094296 | 0.004129 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000988
|
BRD-K71847383-001-12-5
|
ACH-000848
|
JHH7_LIVER
|
HTS002
| 1 | 1.608422 | -0.290429 | 0.135529 | 1.327401 | 0.143795 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000848
|
BRD-K71847383-001-12-5
|
ACH-000785
|
NCIH2126_LUNG
|
HTS002
| 1 | 1.858508 | -0.622198 | 0.131908 | 1.32144 | 0.020083 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000785
|
BRD-K71847383-001-12-5
|
ACH-000544
|
OE21_OESOPHAGUS
|
HTS002
| 1 | 1.524409 | 1.061857 | 0.004385 | 1.449052 | 0.001931 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000544
|
BRD-K71847383-001-12-5
|
ACH-000982
|
GP2D_LARGE_INTESTINE
|
HTS002
| 1 | 2.067322 | -0.454984 | -0.056182 | 1.278291 | 0.00362 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000982
|
BRD-K71847383-001-12-5
|
ACH-000021
|
NCIH1693_LUNG
|
HTS002
| 1 | 1.09997 | -0.088182 | -0.026476 | 1.059635 | 7.037291 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000021
|
BRD-K71847383-001-12-5
|
ACH-000823
|
KYSE140_OESOPHAGUS
|
HTS002
| 1 | 1.45618 | -0.290212 | -0.062462 | 1.138347 | 0.002887 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000823
|
BRD-K71847383-001-12-5
|
ACH-000984
|
HEC6_ENDOMETRIUM
|
HTS002
| 1 | 1.630324 | 0.603439 | -0.068629 | 1.364856 | 0.033217 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000984
|
BRD-K71847383-001-12-5
|
ACH-000579
|
UACC257_SKIN
|
HTS002
| 1 | 1.890047 | -0.091725 | 0.049193 | 1.418633 | 0.020957 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000579
|
BRD-K71847383-001-12-5
|
ACH-001306
|
8305C_THYROID
|
HTS002
| 1 | 1.608385 | 4.061808 | 0.12486 | 1.16195 | 0.755328 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-001306
|
BRD-K71847383-001-12-5
|
ACH-000318
|
TE10_OESOPHAGUS
|
HTS002
| 1 | 1.919951 | -0.048864 | -0.010108 | 1.437761 | 0.010706 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000318
|
BRD-K71847383-001-12-5
|
ACH-000840
|
HCC366_LUNG
|
HTS002
| 1 | 1.204166 | 1.16225 | -0.100847 | 1.138097 | 0.013795 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000840
|
BRD-K71847383-001-12-5
|
ACH-000503
|
BICR16_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 9.353365 | -2.558364 | 0.288094 | 1.069258 | 0.000343 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000503
|
BRD-K71847383-001-12-5
|
ACH-000919
|
IM95_STOMACH
|
HTS002
| 1 | 2.86146 | 0.285706 | 0.024343 | 1.251864 | 112.569045 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000919
|
BRD-K71847383-001-12-5
|
ACH-000822
|
SKMEL24_SKIN
|
HTS002
| 1 | 1.705546 | -0.267401 | 0.040914 | 1.302584 | 0.023145 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000822
|
BRD-K71847383-001-12-5
|
ACH-000292
|
NCIH841_LUNG
|
HTS002
| 1 | 1.936598 | -0.246336 | 0.138943 | 1.330773 | 0.005078 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000292
|
BRD-K71847383-001-12-5
|
ACH-000827
|
WM793_SKIN
|
HTS002
| 1 | 1.34756 | -1.350708 | 0.190575 | 1.215558 | 0.25206 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000827
|
BRD-K71847383-001-12-5
|
ACH-000411
|
769P_KIDNEY
|
HTS002
| 1 | 1.355958 | -0.809507 | 0.226213 | 1.264768 | 0.990264 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000411
|
BRD-K71847383-001-12-5
|
ACH-000139
|
PANC0327_PANCREAS
|
HTS002
| 1 | 0.924605 | 0.568325 | -0.201794 | 0.937375 | 0.001336 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000139
|
BRD-K71847383-001-12-5
|
ACH-000569
|
ISTMES1_PLEURA
|
HTS002
| 1 | 2.089649 | -0.487809 | 0.085823 | 1.194269 | 0.001135 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000569
|
BRD-K71847383-001-12-5
|
ACH-000278
|
COV362_OVARY
|
HTS002
| 1 | 1.219204 | -0.07241 | -0.002248 | 1.096558 | 0.002778 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000278
|
BRD-K71847383-001-12-5
|
ACH-000425
|
UACC62_SKIN
|
HTS002
| 1 | 1.661403 | 0.081608 | -0.022341 | 1.310153 | 0.366081 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000425
|
BRD-K71847383-001-12-5
|
ACH-000013
|
ONCODG1_OVARY
|
HTS002
| 1 | 2.305866 | 0.110774 | -0.160194 | 1.401125 | 142.577303 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000013
|
BRD-K71847383-001-12-5
|
ACH-000730
|
SKMEL5_SKIN
|
HTS002
| 1 | 1.513883 | 0.077037 | -0.02417 | 1.33272 | 0.000027 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000730
|
BRD-K71847383-001-12-5
|
ACH-000500
|
SNU46_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.849929 | -0.417057 | 0.010547 | 1.122608 | 0.000378 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000500
|
BRD-K71847383-001-12-5
|
ACH-000222
|
ASPC1_PANCREAS
|
HTS002
| 1 | 1.128642 | 0.483312 | -0.098323 | 1.077165 | 0.023894 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000222
|
BRD-K71847383-001-12-5
|
ACH-000477
|
MALME3M_SKIN
|
HTS002
| 1 | 1.74188 | -0.159639 | 0.071407 | 1.272825 | 0.002225 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000477
|
BRD-K71847383-001-12-5
|
ACH-000223
|
HCC1937_BREAST
|
HTS002
| 1 | 1.20395 | 0.345411 | -0.128653 | 1.156517 | 0.001242 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000223
|
BRD-K71847383-001-12-5
|
ACH-000495
|
TUHR4TKB_KIDNEY
|
HTS002
| 1 | 1.418975 | 0.158799 | -0.043352 | 1.287589 | 0.000447 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000495
|
BRD-K71847383-001-12-5
|
ACH-000434
|
NCIH1915_LUNG
|
HTS002
| 1 | 1.628387 | -0.45208 | 0.2583 | 1.160206 | 0.00329 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000434
|
BRD-K71847383-001-12-5
|
ACH-000744
|
NCIH1623_LUNG
|
HTS002
| 1 | 1.143532 | -0.089125 | -0.093594 | 1.079561 | 0.937549 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000744
|
BRD-K71847383-001-12-5
|
ACH-000107
|
CAPAN2_PANCREAS
|
HTS002
| 1 | 1.710207 | -0.043703 | 0.015375 | 1.327933 | 0.002309 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000107
|
BRD-K71847383-001-12-5
|
ACH-000516
|
CAL78_BONE
|
HTS002
| 1 | 1.516738 | -0.430137 | -0.010011 | 1.151969 | 0.005363 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000516
|
BRD-K71847383-001-12-5
|
ACH-000182
|
SNU869_BILIARY_TRACT
|
HTS002
| 1 | 1.944138 | -0.444945 | 0.150753 | 1.24563 | 0.003459 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000182
|
BRD-K71847383-001-12-5
|
ACH-000898
|
SNU719_STOMACH
|
HTS002
| 1 | 1.961284 | -0.576289 | 0.060378 | 1.220208 | 0.003281 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000898
|
BRD-K71847383-001-12-5
|
ACH-000040
|
U118MG_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.673846 | -0.163182 | -0.044388 | 1.403579 | 1.033555 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000040
|
BRD-K71847383-001-12-5
|
ACH-000808
|
HUH28_BILIARY_TRACT
|
HTS002
| 1 | 1.608876 | -0.080285 | -0.062346 | 1.276792 | 0.007857 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000808
|
BRD-K71847383-001-12-5
|
ACH-000447
|
NCIH2228_LUNG
|
HTS002
| 1 | 1.136011 | 0.009563 | -0.111553 | 1.053976 | 808,472,476,761,998,500 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000447
|
BRD-K71847383-001-12-5
|
ACH-000715
|
SNU1214_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 2.09 | -0.179554 | -0.024437 | 1.247867 | 0.000059 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000715
|
BRD-K71847383-001-12-5
|
ACH-000186
|
NCIH2444_LUNG
|
HTS002
| 1 | 1.477806 | -0.900742 | -0.041205 | 1.251487 | 0.101544 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000186
|
BRD-K71847383-001-12-5
|
ACH-000542
|
HEYA8_OVARY
|
HTS002
| 1 | 1.765968 | -0.16546 | -0.184065 | 1.414989 | 0.226891 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000542
|
BRD-K71847383-001-12-5
|
ACH-000943
|
RKO_LARGE_INTESTINE
|
HTS002
| 1 | 1.151696 | 0.120367 | -0.000016 | 1.096412 | 0.000677 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000943
|
BRD-K71847383-001-12-5
|
ACH-000174
|
CAL62_THYROID
|
HTS002
| 1 | 1.496954 | -0.679237 | 0.691334 | 1.192906 | 0.024067 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000174
|
BRD-K71847383-001-12-5
|
ACH-000393
|
HLF_LIVER
|
HTS002
| 1 | 2.492667 | -0.145572 | 0.07608 | 1.61281 | 0.005884 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000393
|
BRD-K71847383-001-12-5
|
ACH-000018
|
T24_URINARY_TRACT
|
HTS002
| 1 | 1.831768 | -0.263074 | 0.049117 | 1.295094 | 0.00601 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000018
|
BRD-K71847383-001-12-5
|
ACH-000906
|
ES2_OVARY
|
HTS002
| 1 | 1.487635 | -0.743258 | -0.338532 | 1.281069 | 0.171282 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000906
|
BRD-K71847383-001-12-5
|
ACH-000784
|
KYSE70_OESOPHAGUS
|
HTS002
| 1 | 3.468248 | -0.454166 | 0.015226 | 1.315094 | 0.000345 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000784
|
BRD-K71847383-001-12-5
|
ACH-000265
|
KP4_PANCREAS
|
HTS002
| 1 | 2.115068 | -0.0738 | -0.037106 | 1.548068 | 0.04907 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000265
|
BRD-K71847383-001-12-5
|
ACH-000880
|
AGS_STOMACH
|
HTS002
| 1 | 1.323669 | 0.079653 | -0.01807 | 1.168073 | 0.029309 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000880
|
BRD-K71847383-001-12-5
|
ACH-000961
|
ISHIKAWAHERAKLIO02ER_ENDOMETRIUM
|
HTS002
| 1 | 1.635233 | -4.698613 | 0.805178 | 1.229801 | 0.020426 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000961
|
BRD-K71847383-001-12-5
|
ACH-000847
|
HGC27_STOMACH
|
HTS002
| 1 | 1.107848 | -0.078207 | -0.303913 | 1.060393 | 1.768253 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000847
|
BRD-K71847383-001-12-5
|
ACH-000896
|
647V_URINARY_TRACT
|
HTS002
| 1 | 1.424256 | 0.073293 | -0.012503 | 1.234028 | 0.004488 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000896
|
BRD-K71847383-001-12-5
|
ACH-000685
|
L33_PANCREAS
|
HTS002
| 1 | 1.602589 | -2.121454 | 0.087234 | 1.500916 | 1.974056 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000685
|
BRD-K71847383-001-12-5
|
ACH-000376
|
SF295_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.179642 | -0.133328 | -0.27156 | 1.130573 | 152.421845 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000376
|
BRD-K71847383-001-12-5
|
ACH-000428
|
UO31_KIDNEY
|
HTS002
| 1 | 2.200919 | -0.771553 | -0.108107 | 1.025789 | 0.000064 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000428
|
BRD-K71847383-001-12-5
|
ACH-000749
|
DMS273_LUNG
|
HTS002
| 1 | 2.024865 | 0.082546 | -0.082323 | 1.617646 | 0.00047 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000749
|
BRD-K71847383-001-12-5
|
ACH-000572
|
G361_SKIN
|
HTS002
| 1 | 1.968091 | -0.417417 | 0.239501 | 1.292916 | 0.005791 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000572
|
BRD-K71847383-001-12-5
|
ACH-000457
|
CAL54_KIDNEY
|
HTS002
| 1 | 1.123728 | 0.058488 | -0.00677 | 1.060945 | 0.130323 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000457
|
BRD-K71847383-001-12-5
|
ACH-000601
|
MIAPACA2_PANCREAS
|
HTS002
| 1 | 1.580652 | -0.028907 | 0.035399 | 1.284154 | 0.0179 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000601
|
BRD-K71847383-001-12-5
|
ACH-000651
|
SW620_LARGE_INTESTINE
|
HTS002
| 1 | 1.527829 | -0.540686 | 0.185064 | 1.273207 | 0.095193 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000651
|
BRD-K71847383-001-12-5
|
ACH-000361
|
SKHEP1_LIVER
|
HTS002
| 1 | 1.409461 | -0.183088 | 0.108342 | 1.21608 | 0.14898 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000361
|
BRD-K71847383-001-12-5
|
ACH-000842
|
SW480_LARGE_INTESTINE
|
HTS002
| 1 | 1.594244 | -0.359648 | 0.162307 | 1.172461 | 0.003713 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000842
|
BRD-K71847383-001-12-5
|
ACH-000570
|
YKG1_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 2.17355 | 0.061479 | -0.154803 | 1.550919 | 0.580217 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000570
|
BRD-K71847383-001-12-5
|
ACH-000396
|
J82_URINARY_TRACT
|
HTS002
| 1 | 1.167856 | 0.144567 | -0.076571 | 1.069891 | 0.887262 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000396
|
BRD-K71847383-001-12-5
|
ACH-000777
|
KYSE30_OESOPHAGUS
|
HTS002
| 1 | 1.780203 | -0.35144 | 0.260077 | 1.278052 | 0.009969 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000777
|
BRD-K71847383-001-12-5
|
ACH-000096
|
G401_SOFT_TISSUE
|
HTS002
| 1 | 1.648856 | -0.377861 | 0.112391 | 1.217019 | 0.007959 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000096
|
BRD-K71847383-001-12-5
|
ACH-000955
|
SNU407_LARGE_INTESTINE
|
HTS002
| 1 | 2.549763 | -0.348491 | 0.189183 | 1.797917 | 0.096331 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000955
|
BRD-K71847383-001-12-5
|
ACH-000940
|
AN3CA_ENDOMETRIUM
|
HTS002
| 1 | 1.454095 | 0.02148 | -0.019772 | 1.245016 | 0.000048 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000940
|
BRD-K71847383-001-12-5
|
ACH-001318
|
PLCPRF5_LIVER
|
HTS002
| 1 | 1.623403 | -0.097543 | 0.017441 | 1.298966 | 0.033265 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-001318
|
BRD-K71847383-001-12-5
|
ACH-000332
|
YAPC_PANCREAS
|
HTS002
| 1 | 1.444793 | 0.198488 | -0.022957 | 1.211098 | 0.135587 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000332
|
BRD-K71847383-001-12-5
|
ACH-000839
|
SCABER_URINARY_TRACT
|
HTS002
| 1 | 1.634617 | -0.622596 | -0.064978 | 1.122958 | 0.002231 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000839
|
BRD-K71847383-001-12-5
|
ACH-000178
|
HS766T_PANCREAS
|
HTS002
| 1 | 2.117962 | 0.138319 | 0.041361 | 1.549771 | 0.100026 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000178
|
BRD-K71847383-001-12-5
|
ACH-000421
|
SW837_LARGE_INTESTINE
|
HTS002
| 1 | 2.723479 | 0.255413 | -0.143096 | 1.225303 | 265.340885 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000421
|
BRD-K71847383-001-12-5
|
ACH-000524
|
KURAMOCHI_OVARY
|
HTS002
| 1 | 2.257968 | -0.397461 | 0.144219 | 1.489548 | 0.018151 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000524
|
BRD-K71847383-001-12-5
|
ACH-000153
|
NCIH2052_PLEURA
|
HTS002
| 1 | 1.417734 | 0.121546 | -0.043331 | 1.26227 | 0.000937 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000153
|
BRD-K71847383-001-12-5
|
ACH-000805
|
COLO679_SKIN
|
HTS002
| 1 | 1.993288 | -0.07495 | -0.125977 | 1.471299 | 0.019695 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000805
|
BRD-K71847383-001-12-5
|
ACH-000429
|
A704_KIDNEY
|
HTS002
| 1 | 0.975675 | 0.11513 | -0.215958 | 0.983198 | 0.000061 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000429
|
BRD-K71847383-001-12-5
|
ACH-000108
|
KP3_PANCREAS
|
HTS002
| 1 | 1.266956 | -3.329742 | 0.183945 | 1.177258 | 0.383661 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000108
|
BRD-K71847383-001-12-5
|
ACH-000939
|
SKUT1_SOFT_TISSUE
|
HTS002
| 1 | 1.548814 | -0.201182 | 0.107034 | 1.323542 | 0.542851 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000939
|
BRD-K71847383-001-12-5
|
ACH-000323
|
42MGBA_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.655581 | -0.20409 | 0.055456 | 1.233443 | 0.003418 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000323
|
BRD-K71847383-001-12-5
|
ACH-000219
|
A375_SKIN
|
HTS002
| 1 | 1.461794 | -0.303079 | 0.310451 | 1.221613 | 0.057206 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000219
|
BRD-K71847383-001-12-5
|
ACH-000054
|
HT1080_SOFT_TISSUE
|
HTS002
| 1 | 1.128936 | -0.112964 | -0.02667 | 1.073308 | 0.955028 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000054
|
BRD-K71847383-001-12-5
|
ACH-000302
|
SNU1077_ENDOMETRIUM
|
HTS002
| 1 | 3.514349 | -0.247353 | -0.000334 | 1.372369 | 0.000034 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000302
|
BRD-K71847383-001-12-5
|
ACH-000324
|
JHOC5_OVARY
|
HTS002
| 1 | 1.39086 | -1.632562 | 0.21977 | 1.308182 | 1.312257 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000324
|
BRD-K71847383-001-12-5
|
ACH-000164
|
PANC1_PANCREAS
|
HTS002
| 1 | 1.314857 | -0.026872 | -0.037701 | 1.143519 | 0.000106 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000164
|
BRD-K71847383-001-12-5
|
ACH-000549
|
SNU1076_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.763049 | -0.218239 | 0.042705 | 1.289129 | 0.006623 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000549
|
BRD-K71847383-001-12-5
|
ACH-000650
|
IGR37_SKIN
|
HTS002
| 1 | 1.718212 | -0.221926 | -0.329949 | 1.321186 | 0.027465 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000650
|
BRD-K71847383-001-12-5
|
ACH-000217
|
JHH6_LIVER
|
HTS002
| 1 | 2.099282 | -0.154255 | -0.028402 | 1.362635 | 0.000644 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000217
|
BRD-K71847383-001-12-5
|
ACH-000463
|
NCIH460_LUNG
|
HTS002
| 1 | 1.398672 | 0.014835 | -0.058375 | 1.20806 | 0.000213 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000463
|
BRD-K71847383-001-12-5
|
ACH-000748
|
SJSA1_BONE
|
HTS002
| 1 | 1.472746 | -0.033403 | 0.000362 | 1.223345 | 0.002851 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000748
|
BRD-K71847383-001-12-5
|
ACH-000788
|
A2058_SKIN
|
HTS002
| 1 | 1.257768 | 0.083951 | -0.082503 | 1.139931 | 0.009808 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000788
|
BRD-K71847383-001-12-5
|
ACH-000545
|
VMCUB1_URINARY_TRACT
|
HTS002
| 1 | 1.230556 | -0.330321 | -0.069765 | 1.155792 | 1.114415 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000545
|
BRD-K71847383-001-12-5
|
ACH-000762
|
YD38_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.793875 | -0.086831 | -0.070986 | 1.394286 | 0.06683 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000762
|
BRD-K71847383-001-12-5
|
ACH-000792
|
BFTC909_KIDNEY
|
HTS002
| 1 | 3.423108 | -0.328087 | 0.188778 | 1.488262 | 0.000567 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000792
|
BRD-K71847383-001-12-5
|
ACH-000211
|
DAOY_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 2.524189 | 0.210277 | -0.019123 | 1.289017 | 128.817277 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000211
|
BRD-K71847383-001-12-5
|
ACH-000936
|
EFO27_OVARY
|
HTS002
| 1 | 1.547973 | 0.110772 | -0.013901 | 1.395708 | 0.000012 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000936
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.